Description
Cell to transfect:
Designations: MOLT-4
Cell Synonyms: CRL-1582, NCI60, NCI-60, human leukemia cell
Organism: Homo sapiens (human)
Tissue: T lymphoblast; acute lymphoblastic leukemia
Age: 19 years
Gender: male
Morphology: lymphoblast
Growth properties: suspension
Tumorigenic: yes, in untreated nude mice, anti lymphocyte serum treated mice and X-irradiated mice.
Products: high levels of terminal deoxynucleotidyl transferase (TdT)
Depositor: J. Minowada
The line was established from cells taken from a patient in relapse. The patient had received prior multidrug chemotherapy.There is a G -> A mutation at codon 248 of the p53 gene. P53 is not expressed. The cells do not produce immunoglobulin or Epstein-Barr virus.
MOLT-4 is one of the cell lines of the NCI-60 panel which represents different cancer types and has been widely utilized for drug screening and molecular target identification.
Features of The Transfection Reagent:
- Broad spectrum for the transfection of large plasmid, mRNA, siRNA, and/or other type of nucleic acids, which is best for co-transfection of different type and/or size of nucleic acids.
- Unique formulation-maximize transfection performance in MOLT-4 Cells.
- Extremely gentle to cells
- 0.5 ml is able to transfect about 1000 wells of 24-well plate
- Deliver single or multiple plasmids
- Animal-free
- Compatible with serum
- Compatible with transfection in any plate formats
- Reproducible: due to highly controlled chemical synthesis of each of the ingredients, the reagent forms uniformly sized complex particles with nucleic acids. With optimized protocol, our reagent will ensure the reproducible highest transfection results.
- Developed and manufactured by EZ Biosystems, LLC
Data
FIG. 1. High throughput test of transfection efficiency (determined as RLU/mg) on MOLT-4 cells after transfection of luciferase reporter gene by using our 172 proprietary transfection formulas and several most popular commercial transfection reagents. The yellow box showed the results of 4 commercial transfection reagents. The red lines marked our candidate formulas with the highest transfection efficiency for MOLT-4 cells. This test result was confirmed with repeat experiments. The one that showed the optimal balance of potent & low cytotoxicity among those candidate formulas after flow cytometry analysis on the percentage of 7AAD positive cells was later named as this MOLT-4 Cell Avalanche Transfection Reagent.
For Other Cells
MOLT-4 Cell Avalanche® Transfection Reagent (human leukemia cell) can also be used on the following cells with high transfection efficiencies.
293 Cell
293T/17 Cell
NIH/3T3 Cell
3T3-L1 Cell
BALB/3T3 clone A31
3T3-Swiss albino Cell
CT26.WT Cell
NCTC Clone 929 Cell
Recommended protocols for these cells will be provided with the reagent. The protocols usually provide satisfactory transfection efficiency with invisible cytotoxicity. However, optimization may be needed for certain type of cells. Optimizations may include: the amount of DNA and this transfection reagent; cell density; transfection reagent/DNA ratio, or incubation time for the mixture of transfection reagent/DNA etc. For best transfection result, we recommend using the respective cell type/cell line specific Avalanche transfection reagents. Those reagents have been optimized on both recipes and protocols, and have been proved to have the best transfection results for the respective cell lines or primary cells. You can easily find the respective Avalanche transfection reagents specific for your cells by using the filters of our product list.
Additional Information
Weight | 0.5 lbs |
---|---|
Adherence Phenotype | Suspension |
Cell Type | lymphocyte |
Disease | Cancer |
Names starting from | M |
Primary/Cell Line | Cell Line |
Product Sizes | 0.5 ml, 1.5 ml |
Species | Human |
Tissue Sources | Blood |
Subcategories | Cell Type/Cell Line Specific |
Documents
Protocols
MSDS
Citations or Feedback
- Abraham, B. J., Hnisz, D., Weintraub, A. S., Kwiatkowski, N., Li, C. H., Li, Z., . . . Young, R. A. (2017). Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun, 8, 14385. doi:10.1038/ncomms14385
- Hnisz, D., Weintraub, A. S., Day, D. S., Valton, A. L., Bak, R. O., Li, C. H., . . . Young, R. A. (2016). Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science, 351(6280), 1454-1458. doi:10.1126/science.aad9024